Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Frequent mutated B2M, EZH2 , IRF8 , and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Blood Adv (2021) 5 (19): 3760–3775.

https://doi.org/10.1182/bloodadvances.2021005215

Published: 2021

Includes: Supplemental data

Journal Articles

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, B. Dharmaveer Shetty, Konrad J. Cios, Puja C. Arora, Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber

Blood Adv (2021) 5 (17): 3497–3510.

https://doi.org/10.1182/bloodadvances.2020003944

Published: 2021

Includes: Supplemental data

Journal Articles

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance

Justin Anthony Chen, Yanli Hou, Krishna M. Roskin, Daniel A. Arber, Charles D. Bangs, Linda B. Baughn, Athena M. Cherry, Mark D. Ewalt, Andrew Z. Fire, Laure Fresard, Hutton M. Kearney, Stephen B. Montgomery, Robert S. Ohgami, Kathryn E. Pearce, Beth A. Pitel, Jason D. Merker, Jason Gotlib

Blood Adv (2021) 5 (17): 3492–3496.

https://doi.org/10.1182/bloodadvances.2020004174

Published: 2021

Includes: Supplemental data

Journal Articles

Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis

Derek C. H. Chan, Joshua Xu, Ana Vujovic, Nicholas Wong, Victor Gordon, Laura P. M. H. de Rooij, Steven Moreira, Cailin E. Joyce, Jose La Rose, María-José Sandí, Bradley W. Doble, Carl D. Novina, Robert K. Rottapel, Kristin J. Hope

Blood Adv (2021) 5 (16): 3120–3133.

https://doi.org/10.1182/bloodadvances.2020002539

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma

Xinjie Xu, Christian N. Paxton, Robert J. Hayashi, Kimberly P. Dunsmore, Stuart S. Winter, Stephen P. Hunger, Naomi J. Winick, William L. Carroll, Mignon L. Loh, Meenakshi Devidas, Thomas G. Gross, Catherine M. Bollard, Sherrie L. Perkins, Rodney R. Miles

Blood Adv (2021) 5 (14): 2890–2900.

https://doi.org/10.1182/bloodadvances.2021004334

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency

Marja W. Wessels, Marjon H. Cnossen, Thamar B. van Dijk, Nynke Gillemans, K. L. Juliëtte Schmidt, Kirsten van Lom, Divya S. Vinjamur, Steven Coyne, Ryo Kurita, Yukio Nakamura, Stella A. de Man, Rolph Pfundt, Zakia Azmani, Rutger W. W. Brouwer, Daniel E. Bauer, Mirjam C. G. N. van den Hout, Wilfred F. J. van IJcken, Sjaak Philipsen

Blood Adv (2021) 5 (9): 2339–2349.

https://doi.org/10.1182/bloodadvances.2020003753

Published: 2021

Includes: Supplemental data

Journal Articles

LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα

Kensaku Kohrogi, Shinjiro Hino, Akihisa Sakamoto, Kotaro Anan, Ryuta Takase, Hirotaka Araki, Yuko Hino, Kazutaka Araki, Tetsuya Sato, Kimitoshi Nakamura, Mitsuyoshi Nakao

Blood Adv (2021) 5 (9): 2305–2318.

https://doi.org/10.1182/bloodadvances.2020003521

Published: 2021

Includes: Supplemental data

Journal Articles

Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors

Amanda L. Evans, Amanda Dalby, Holly R. Foster, Daniel Howard, Amie K. Waller, Momal Taimoor, Moyra Lawrence, Souradip Mookerjee, Marcus Lehmann, Annie Burton, Jorge Valdez, Jonathan Thon, Joseph Italiano, Thomas Moreau, Cedric Ghevaert

Blood Adv (2021) 5 (7): 1977–1990.

https://doi.org/10.1182/bloodadvances.2020003236

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature

Blood Adv (2021) 5 (4): 1059–1068.

https://doi.org/10.1182/bloodadvances.2020003172

Published: 2021

Includes: Supplemental data

Journal Articles

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

Blood Adv (2021) 5 (3): 760–770.

https://doi.org/10.1182/bloodadvances.2020003195

Published: 2021

Includes: Supplemental data

Journal Articles

Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Emery H. Bresnick, Mabel M. Jung, Koichi R. Katsumura

Blood Adv (2020) 4 (18): 4584–4592.

https://doi.org/10.1182/bloodadvances.2020002953

Published: 2020

Journal Articles

Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy

Aaron J. Wilk, Nancy Lynn-Benner Weidenbacher, Rosemary Vergara, Ole A. W. Haabeth, Ronald Levy, Robert M. Waymouth, Paul A. Wender, Catherine A. Blish

Blood Adv (2020) 4 (17): 4244–4255.

https://doi.org/10.1182/bloodadvances.2020002355

Published: 2020

Includes: Supplemental data

Journal Articles

Predictive modeling of complex ABO glycan phenotypes by lectin microarrays

Waseem Q. Anani, Heather E. Ashwood, Anna Schmidt, Robert T. Burns, Gregory A. Denomme, Karin M. Hoffmeister

Blood Adv (2020) 4 (16): 3960–3970.

https://doi.org/10.1182/bloodadvances.2020002051

Published: 2020

Includes: Supplemental data

Journal Articles

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD

Eleonora Latis, David Michonneau, Claire Leloup, Hugo Varet, Régis Peffault de Latour, CRYOSTEM Consortium, Elisabetta Bianchi, Gérard Socié, Lars Rogge

Blood Adv (2020) 4 (16): 3927–3942.

https://doi.org/10.1182/bloodadvances.2019001032

Published: 2020

Includes: Supplemental data

Journal Articles

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli

Blood Adv (2020) 4 (15): 3677–3687.

https://doi.org/10.1182/bloodadvances.2020002175

Published: 2020

Includes: Supplemental data

Journal Articles

Exploitable metabolic dependencies in MLL-ENL–induced leukemia

Maria-Paz Garcia-Cuellar, Jennifer Lawlor, Martin Böttcher, Dimitrios Mougiakakos, Markus Metzler, Robert K. Slany

Blood Adv (2020) 4 (15): 3626–3638.

https://doi.org/10.1182/bloodadvances.2020001710

Published: 2020

Includes: Supplemental data

Journal Articles

Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D′D3 and D4 domains

Monica Sacco, Stefano Lancellotti, Mattia Ferrarese, Francesco Bernardi, Mirko Pinotti, Maira Tardugno, Erica De Candia, Leonardo Di Gennaro, Maria Basso, Betti Giusti, Massimiliano Papi, Giordano Perini, Giancarlo Castaman, Raimondo De Cristofaro

Blood Adv (2020) 4 (14): 3405–3415.

https://doi.org/10.1182/bloodadvances.2020002334

Published: 2020

Includes: Supplemental data

Journal Articles

Low VWF: insights into pathogenesis, diagnosis, and clinical management

James S. O’Donnell

Blood Adv (2020) 4 (13): 3191–3199.

https://doi.org/10.1182/bloodadvances.2020002038

Published: 2020

Journal Articles

Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms

Ashley Cartwright, Simon J. Webster, Annika de Jong, Richard J. Dirven, Lisa D. S. Bloomer, Ahlam M. AL-Buhairan, Ulrich Budde, Christer Halldén, David Habart, Jenny Goudemand, Ian R. Peake, Jeroen C. J. Eikenboom, Anne C. Goodeve, Daniel J. Hampshire

Blood Adv (2020) 4 (13): 2979–2990.

https://doi.org/10.1182/bloodadvances.2018027813

Published: 2020

Includes: Supplemental data

Journal Articles

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden

Theodoros Karantanos, Shruti Chaturvedi, Evan M. Braunstein, Jerry Spivak, Linda Resar, Styliani Karanika, Donna M. Williams, Ophelia Rogers, Christopher D. Gocke, Alison R. Moliterno

Blood Adv (2020) 4 (12): 2567–2576.

https://doi.org/10.1182/bloodadvances.2019001407

Published: 2020

Includes: Supplemental data

NARROW

Frequent mutated B2M, EZH2 , IRF8 , and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance

Arhgef2 regulates mitotic spindle orientation in hematopoietic stem cells and is essential for productive hematopoiesis

Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma

Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency

LSD1 defines erythroleukemia metabolism by controlling the lineage-specific transcription factors GATA1 and C/EBPα

Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors

Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

Human GATA2 mutations and hematologic disease: how many paths to pathogenesis?

Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy

Predictive modeling of complex ABO glycan phenotypes by lectin microarrays

Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Exploitable metabolic dependencies in MLL-ENL–induced leukemia

Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D′D3 and D4 domains

Low VWF: insights into pathogenesis, diagnosis, and clinical management

Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only